RBC Capital Reiterates Outperform on Legend Biotech, Maintains $83 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Leonid Timashev reiterated an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintained an $83 price target.
June 16, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev reiterated an Outperform rating on Legend Biotech and maintained an $83 price target.
The reiteration of an Outperform rating by RBC Capital's analyst Leonid Timashev indicates a positive outlook for Legend Biotech. The maintained $83 price target suggests that the stock has potential for growth in the short term, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100